The burgeoning landscape of emerging treatments for metabolic management has seen the rise of both retatrutide and tirzepatide, both dual mode agonists targeting the GLP-1 and GIP receptors. While sharing a alike https://shaunalywf247346.wikipublicity.com/7796517/retatrutide_vs_tirzepatide_a_comparative_analysis